Levi & Korsinsky, LLP announces that it has commenced an investigation of KemPharm, Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors. On April 16, 2015, KemPharm sold 5.09 million shares in its Initial Public Offering, raising $60 million in new capital. Then on May 5, 2016, KemPharm announced that two committees of the U.S. Food and Drug Administration had determined that one of the Company's drugs, Apadaz, should be approved for its proposed indication of the management of acute pain that requires an opiod, but voted against inclusion of abuse-deterrent labeling for the product. Following this news, KemPharm's stock fell 56% to close at $6.91 per share on May 6. 2016. Since the IPO, KemPharm's stock has fallen from a high of $23.63 per share in September of 2015 to a close of $3.50 per share on October 25, 2016. To obtain additional information about the investigation, go to: http://zlk.9nl.com/kempharm-kmph or contact Joseph E. Levi, Esq. either via email at email@example.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.